GILEAD SCIENCES INC (GILD)
US3755581036 - Common Stock
The P3 App: Empowering and Elevating Underprivileged Youth from Socioeconomically Disadvantaged Areas Through Innovative Mentorship
CHICAGO - May 18, 2024 - PRLog -- The Pulse of Perseverance alongside Gilead is proud to announce the launch of the P3 mobile app, a pioneering platform unveiled at our signature benefit event on May 16, now available on the app store. Designed to transform the landscape of mentorship, the P3 app connects students from underprivileged backgrounds with mentors in underrepresented fields, fostering a supportive community and opening doors to internships and career opportunities.Amidst the backdrop of systemic barriers that often hinder the academic and professional aspirations of Black children, the P3 app stands as a beacon of hope and opportunity. It not only bridges the gap in resource access but also challenges the status quo by providing a direct funnel to success in advanced fields where youth from socioeconomically disadvantaged areas are vastly underrepresented.Features of the P3 App:
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
Penny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns.
See Which Of The Latest 13F Filers Holds Gilead Sciences
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
One stock is dragging down the S&P 500's earnings growth
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.
Why NASDAQ:GILD qualifies as a good dividend investing stock.
Why GILEAD SCIENCES INC (NASDAQ:GILD) is a Top Pick for Dividend Investors.
Noteworthy Wednesday Option Activity: GILD, BKNG, TGNA
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back
If you want your shot at significant upside, speculate on these stocks near 52-week lows that can prove the critics wrong.
Nasdaq 100 Movers: FTNT, AMGN
Interesting GILD Put And Call Options For June 14th
Gilead cuts jobs, trims drugs amid deeper biopharma pullback
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar
These biotech stocks seem to be rich with intriguing growth plays going for very reasonable multiples this May.
Gilead Sciences to Present at Upcoming Investor Conferences
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
U.S. Lags Behind Other Countries in Hepatitis-C Treatment
Despite an arsenal of drugs, many Americans are still unaware of their infections until it’s too late. A Biden initiative languishes without Congressional approval.
June 7th Options Now Available For Gilead Sciences (GILD)
3 Dividend Stocks to Buy at a 52-Week Low in April
Explore these three dividend stocks trading near their 52-week lows, presenting compelling opportunities for income-oriented investors.
